Scinai Immunotherapeutics Ltd. (SCNI) Research
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Market snapshot
- Symbol
- SCNI
- Price
- $0.32
- Day change
- -4.60%
- Market cap
- $422.9K
- P/E ratio
- -0.00x
- 52-week range
- 0.3-3.48
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Recent news
- Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attention on its near-term funding runway. Here's what investors need to know.
Peer companies
Recent insider activity
- GERMAIN MARK — A-Award (120000000 shares) on 2026-06-16
- Reichman Amir — A-Award (400000000 shares) on 2026-06-16
- Mark Elad — trade (0 shares) on 2026-03-18
- Mark Elad — trade (13460984 shares) on 2026-03-18
- MARGOLIN YAEL — trade (200000 shares) on 2026-03-18
Open Scinai Immunotherapeutics Ltd. (SCNI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.